Abstract
Dystonia in cerebral palsy (DCP) is a common, debilitating, but understudied condition. The CP community (people with CP and caregivers) is uniquely equipped to help determine the research questions that best address their needs. We developed a community-driven DCP research agenda using the well-established James Lind Alliance methodology. CP community members, researchers, and clinicians were recruited through multiple advocacy, research, and professional organizations. To ensure shared baseline knowledge, participants watched webinars outlining our current knowledge on DCP prepared by a Steering Group of field experts (cprn.org/research-cp-dystonia-edition). Participants next submitted their remaining uncertainties about DCP. These were vetted by the Steering Group and consolidated to eliminate redundancy to generate a list of unique uncertainties, which were then prioritized by the participants. The top-prioritized uncertainties were aggregated into themes through iterative consensus-building discussions within the Steering Group. 166 webinar viewers generated 67 unique uncertainties. 29 uncertainties (17 generated by community members) were prioritized higher than their randomly matched pairs. These were coalesced into the following top 10 DCP research themes: (1) develop new treatments; (2) assess rehabilitation, psychological, and environmental management approaches; (3) compare effectiveness of current treatments; (4) improve diagnosis and severity assessments; (5) assess the effect of mixed tone (spasticity and dystonia) in outcomes and approaches; (6) assess predictors of treatment responsiveness; (7) identify pathophysiologic mechanisms; (8) characterize the natural history; (9) determine the best treatments for pain; and (10) increase family awareness. This community-driven research agenda reflects the concerns most important to the community, both in perception and in practice. We therefore encourage future DCP research to center around these themes. Furthermore, noting that community members (not clinicians or researchers) generated the majority of top-prioritized uncertainties, our results highlight the important contributions community members can make to research agendas, even beyond DCP.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 237-245 |
| Number of pages | 9 |
| Journal | Neurology |
| Volume | 99 |
| Issue number | 6 |
| DOIs | |
| State | Published - Aug 9 2022 |
Funding
P. Gross has received research support from the University of Utah and is a site principal investigator for a National Institute of Neurological Disorders and Stroke–funded study (5R01NS106298-03). M.C. Kruer serves as a consultant for Aeglea, PTC Therapeutics, CoA Therapeutics, and Merz, reviews grants for the US Department of Defense, and receives grant funding from the National Institute of Neurological Disorders and Stroke (R01-NS106298-02). J.W. Mink serves on an independent Data and Safety Monitoring Board for a study in “Dyskinetic CP” sponsored by TEVA. B.R. Aravamuthan serves as a consultant for Neurocrine Biosciences and receives grant funding from the National Institute of Neurological Disorders and Stroke (5K12NS098482-02 and 1K08NS117850-01A1). All other authors report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.
ASJC Scopus subject areas
- Clinical Neurology